# Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis

> **NCT02424396** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 30 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** IL2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02424396
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-13
- **Primary completion:** 2019-10-11
- **Final completion:** 2020-06-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02424396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02424396, "Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT02424396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*